These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8542868)

  • 1. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis).
    Zeymer U; von Essen R; Tebbe U; Michels HR; Jessel A; Vogt A; Roth M; Appel KF; Neuhaus KL
    Eur Heart J; 1995 Jul; 16 Suppl D():22-7. PubMed ID: 8542868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
    von Essen R; Zeymer U; Tebbe U; Jessel A; Kwasny H; Mateblowski M; Niederer W; Wagner J; Mäurer W; von Leitner ER; Haerten K; Roth M; Neuhaus KL
    Coron Artery Dis; 1998; 9(5):265-72. PubMed ID: 9710686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
    Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
    Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
    Neuhaus KL; von Essen R; Tebbe U; Jessel A; Heinrichs H; Mäurer W; Döring W; Harmjanz D; Kötter V; Kalhammer E
    Circulation; 1994 Oct; 90(4):1638-42. PubMed ID: 7923646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.
    Neuhaus KL; Molhoek GP; Zeymer U; Tebbe U; Wegscheider K; Schröder R; Camez A; Laarman GJ; Grollier GM; Lok DJ; Kuckuck H; Lazarus P
    J Am Coll Cardiol; 1999 Oct; 34(4):966-73. PubMed ID: 10520777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
    Zeymer U; Mateblowski M; Neuhaus KL
    Eur Heart J; 1996 Dec; 17(12):1836-40. PubMed ID: 8960425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
    Zeymer U; Neuhaus KL
    Z Kardiol; 2000; 89 Suppl 4():IV30-40. PubMed ID: 10810775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
    Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
    J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
    Antman EM
    Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
    Antman EM
    Circulation; 1994 Oct; 90(4):1624-30. PubMed ID: 7923644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
    Park SJ
    Am J Cardiol; 1998 Sep; 82(6):811-3, A10. PubMed ID: 9761098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.
    Neuhaus KL; Feuerer W; Jeep-Tebbe S; Niederer W; Vogt A; Tebbe U
    J Am Coll Cardiol; 1989 Nov; 14(6):1566-9. PubMed ID: 2509531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
    Lee LV
    Am J Cardiol; 1995 Jan; 75(1):7-13. PubMed ID: 7801868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
    French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
    Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.